International pharmaceutical companies – Angelini and Glenmark – become members of AIPM

April 14, 2015 – Association of international pharmaceutical manufacturers (AIPM) announces extension to its member list. The decision to include two new companies – Angelini and Glenmark, was made during AIPM General Managers Meeting.
 

“We are glad to welcome amongst the new AIPM members those companies who fully share the values ​​and principles of the Association, and who pay particular attention to the support and development of innovation, ethical standards of business conduct and social responsibility. In principle, the expansion of the Association has never been an end in itself for us. However, it is good to know that international pharmaceutical companies working in Russia do not consider their activity in isolation from the professional community in the face of AIPM, and the number of participants is steadily increasing over the years”, - said Vladimir Shipkov, AIPM Executive Director.

"Throughout my professional career, I worked in several AIPM member companies. It is an honor to be back to our expert community. Based on my personal experience, I would like to note that the activities of the Association are always focused on results and bring significant contribution to the development of the industry. Angelini has more than 40 years experience in research and development in the pharmaceutical sector, from the design of original molecules to their registration as drugs. This work is done at the Angelini Research Centre in S. Palomba, Rome, and at both public and private centers of scientific excellence, though cooperation with leading scientist worldwide. Professional competence, competitiveness, involvement and collaboration at every level, and ethicalness are the founding values of the company spirit. These make it possible to address every kind of challenge, whether inside or outside the company, rapidly and efficiently, and here we are absolutely consisted with AIPM”, - said Rita Bobro, General Director of Angelini Pharma Rus LLC.

“One of the key factors differentiating Glenmark is the focus on scientific research and development of innovative products. Our R&D centers, where development of innovative chemical and biological molecules takes place, are located in India, United Kingdom and Switzerland. Russia is among the top 5 key markets for our company. We are proud of the projects which we have already realized in the Russian Federation, and we have ambitious short and long term plans. The work in our company is built in accordance with best practices and standards. I am confident that membership in AIPM will allow us to take the company to the new level. In return, by being an AIPM member, we hope to be able to contribute to further fruition and excellence of the Association, which brings together great companies who work for the benefit of our patients in Russia and globally”, - stated Elena Astakhova, General Director of Glenmark, Russia. 

About:

Angelini, a privately owned, international group, is leader in the healthcare and wellbeing market in the pharmaceutical and mass-market sectors. Angelini was founded in Italy at the beginning of the 20th century. Today, it is an international group with branches in 20 countries and worldwide product distribution. Guided by the President Francesco Angelini, the group employs about 4000 people. In 2013 the consolidated turnover was over 1.4 billion Euros. In the Pharmaceutical sector, Angelini focuses mainly on pain relief, inflammation, CNS, cold & flu, oral care & sore throat, gynaecology, disinfection. The most widespread and well-known international brands are Tantum, Trittico and Aulin. In November 2014 Angelini registered its company in Russia as “Angelini Pharma Rus LLC”.

Glenmark Pharmaceuticals Ltd. is a research-driven, global, integrated pharmaceutical company. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues (SCRIP 100 Rankings published in the year 2014). Glenmark is one of the leading players in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development, which are primarily focused on the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain]. Company employs over 11 000 people in 80 countries; has 14 manufacturing facilities (finished dosage forms and APIs) and six R&D centres.

Association of International Pharmaceutical Manufacturers (AIPM) comprises 59 international pharmaceutical companies that provide over 80% of the world’s pharmaceutical products and over 60% of medicines imported to the Russian Federation.

For more information please contact:

Irina Sheykkha, 
AIPM Communications Director 
tel.: +7 (495) 933 70 40
e-mail: I.Sheykkha@aipm.org

Julia Semenina,

AIPM PR Manager 
tel.: +7 (495) 933 70 40
mob.: +7 (903) 241 79 81

e-mail: j.semenina@aipm.org